Pesquisar
Beigene Ltd
ONCAdicionar à lista de desejos
311.230USD
-3.840-1.22%
Horário de mercado （ET）Cotações atrasadas em 15 min
31.83BValor de mercado
66.67P/L TTM
Mais detalhes de Beigene Ltd Empresa
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Informações de Beigene Ltd
Código da empresaONC
Nome da EmpresaBeOne Medicines AG
Data de listagemMar 02, 2016
CEOOyler (John Victor)
Número de funcionários11000
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 02
Endereçoc/o BeOne Medicines I GmbH
CidadeBASEL
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísSwitzerland
Código postal4051
Telefone41616851900
Sitehttps://beonemedicines.com/
Código da empresaONC
Data de listagemMar 02, 2016
CEOOyler (John Victor)
Executivos da empresa Beigene Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Aaron Rosenberg
Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Matthew (Matt) Shaulis
Mr. Matthew (Matt) Shaulis
General Manager, North America
General Manager, North America
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Marcello Damiani
Mr. Marcello Damiani
Chief Technology Officer
Chief Technology Officer
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Aaron Rosenberg
Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Matthew (Matt) Shaulis
Mr. Matthew (Matt) Shaulis
General Manager, North America
General Manager, North America
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Outro
-1.31B
-92.66%
Por RegiãoUSD
Nome
Receita
Proporção
United States
754.86M
53.45%
China
439.88M
31.15%
Europe
166.58M
11.79%
ROW
50.97M
3.61%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
Outro
-1.31B
-92.66%
Distribuição de ações
Atualizado em: seg, 11 de mai
Atualizado em: seg, 11 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
Capital International Investors
4.66%
PRIMECAP Management Company
4.53%
Fidelity Management & Research Company LLC
3.61%
Outro
61.91%
Investidores
Investidores
Proporção
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
Capital International Investors
4.66%
PRIMECAP Management Company
4.53%
Fidelity Management & Research Company LLC
3.61%
Outro
61.91%
Tipos de investidores
Investidores
Proporção
Investment Advisor
18.12%
Corporation
17.28%
Hedge Fund
8.90%
Investment Advisor/Hedge Fund
3.76%
Sovereign Wealth Fund
0.84%
Research Firm
0.77%
Private Equity
0.07%
Venture Capital
0.02%
Family Office
0.02%
Outro
50.23%
Participação acionária institucional
Atualizado em: dom, 5 de abr
Atualizado em: dom, 5 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
602
40.42M
36.84%
+1.96M
2025Q4
585
34.35M
31.32%
-4.52M
2025Q3
565
40.04M
36.51%
-2.11M
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Amgen Inc
18.94M
17.27%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.02%
--
--
Dec 31, 2025
Capital International Investors
5.11M
4.66%
+67.81K
+1.34%
Dec 31, 2025
PRIMECAP Management Company
4.98M
4.54%
-99.88K
-1.97%
Dec 31, 2025
Fidelity Management & Research Company LLC
3.96M
3.61%
+205.75K
+5.48%
Dec 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
Dec 31, 2025
Temasek Holdings Pte. Ltd.
919.59K
0.84%
-91.88K
-9.08%
Dec 31, 2025
T. Rowe Price International Ltd
805.96K
0.73%
-135.89K
-14.43%
Dec 31, 2025
T. Rowe Price Associates, Inc.
566.72K
0.52%
-122.00K
-17.71%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
547.72K
0.5%
+157.14K
+40.23%
Dec 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
VanEck Biotech ETF
4.03%
First Trust NYSE Arca Biotechnology Index Fund
3.26%
Tema Oncology ETF
2.65%
Global X Aging Population ETF
2.41%
Virtus LifeSci Biotech Products ETF
1.8%
iShares Biotechnology ETF
1.71%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.02%
National Security Emerging Markets Index ETF
0.83%
Capital Group Global Equity ETF
0.79%
Ver Mais
VanEck Biotech ETF
Proporção4.03%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.26%
Tema Oncology ETF
Proporção2.65%
Global X Aging Population ETF
Proporção2.41%
Virtus LifeSci Biotech Products ETF
Proporção1.8%
iShares Biotechnology ETF
Proporção1.71%
ProShares Ultra Nasdaq Biotechnology
Proporção1.02%
Invesco Nasdaq Biotechnology ETF
Proporção1.02%
National Security Emerging Markets Index ETF
Proporção0.83%
Capital Group Global Equity ETF
Proporção0.79%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
